New biomarker identified for early diagnosis of lung cancer

May 8, 2018, Elsevier
Immunoblot analysis using anti-CKAP4 antibody with whole-cell lysates from A549, RERF-LC-AI, N231, and LCN1, and lung tissue samples. A) CKAP4 protein is detected at approximately 63 kDa in all lung cancer cells. B) CKAP4 protein is also detected at approximately 63 kDa in culture supernatants of A549 and RERF-LC-AI cells. C) The CKAP4 protein is expressed only in lung cancer tissues, and not in their normal counterparts. T: tumor tissue, N: normal lung tissue. CKAP4 was observed at various intensities in the cytoplasm of lung cancer cells (D: A549, E: RERF LC-AI, F: N231, G: LCN1) and tissues (H: AC, I: SCC), but not in normal lung epithelium (J: alveolar epithelium, K: bronchial epithelium). Credit: The American Journal of Pathology

High levels of cytoskeleton-associated protein 4 (CKAP4) have been identified in the blood of patients with lung cancer. In a novel study in The American Journal of Pathology investigators found that CKAP4 levels were significantly higher in patients with lung cancer than in healthy individuals. They further determined that CKAP4 levels are already elevated in the blood of patients with stage I disease, making it a potential noninvasive diagnostic marker that could change current practices in the diagnosis and treatment of some types of lung cancer, including non-small-cell lung cancer and squamous cell carcinoma, and improve patient outcomes.

Lung is the leading cause of cancer deaths in both men and women in the United States and worldwide. The disease is associated with a poor prognosis because most cancers are only diagnosed at an advanced stage.

"The identification of at an early stage of cancer when it can be treated surgically is extremely important to improve prognosis," explained Yuichi Sato, PhD, Department of Molecular Diagnostics, Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa, Japan, who led the study. "We need better biomarkers for early diagnosis."

Current biomarkers for lung cancer include carcinoma embryonic antigen (CEA), sialyl Lewis X antigen (SLX), squamous cell carcinoma (SCC) antigen, and cytokeratin fragment (CYFRA) 21-1, but these are not sensitive enough to detect tumors early, according to co-investigator Ryo Nagashio, PhD, from the Kitasato University School of Allied Health Sciences. "The results of our study provide evidence that the CKAP4 protein may be a novel early sero-diagnostic marker for lung cancer."

Researchers performed reverse-phase protein array analysis using a monoclonal antibody designated as KU-Lu-1 antibody on the blood of 271 and 100 healthy individuals. KU-Lu-1 reacted only with tumor cells and tumor stromal fibroblasts in lung cancer tissues and not with normal lung tissues. Using immunoprecipitation and mass spectrometry, they confirmed that the KU-Lu-1 antibody recognized CKAP4 in and tissues, and its secretion into the culture supernatant was also confirmed. In addition, a validation set consisting of samples from 100 patients with lung cancer and 38 healthy controls was also studied.

CKAP4 was recently identified as a receptor of Dickkopf1 (DKK1). Expressions of DKK1 and CKAP4 were frequently observed in tumor lesions of human pancreatic and lung cancers, and the simultaneous expression of both proteins in tumor tissues was inversely correlated with prognosis and relapse-free survival.

Across disease stages I-IV, the sensitivities of serum CEA, CYFRA, and SCCA are reported with 30 to 52, 17 to 82, and 24 to 39 percent, respectively. In this study, the sensitivity of serum CKAP4 was 81 percent in the training set and 69 percent in the validation set. These rates are higher than those of the current sero-diagnostic markers. Furthermore, the sensitivity of serum CKAP4 was also high even in stage I and .

"The use of CKAP4 as a biomarker could change current practices regarding the treatment of patients, and the diagnostic accuracies may be markedly improved by the combination of CKAP4 and conventional markers," concluded Dr. Sato.

Explore further: Blood biomarker may detect lung cancer

More information: "Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer," American Journal of Pathology (2018). DOI: 10.1016/j.ajpath.2018.03.007

Related Stories

Blood biomarker may detect lung cancer

October 21, 2014
A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

New marker identified for early diagnosis of lung cancer

September 17, 2013
A protein called isocitrate dehydrogenase (IDH1) is present at high levels in lung cancers and can be detected in the blood, making it a noninvasive diagnostic marker for lung cancers, according to a study published in Clinical ...

Blood protein in lung cancer could improve diagnosis and treatment

March 2, 2011
Scientists are reporting discovery of a protein in the blood of lung cancer patients that could be used in a test for the disease — difficult to diagnose in its earliest and most treatable stages — and to develop ...

Prognostic factors identified for peripheral squamous cell carcinomas of the lung

October 24, 2014
A better survival outcome is associated with low blood levels of squamous cell carcinoma antigen, or absence of tumor invasion either into the space between the lungs and chest wall or into blood vessels of individuals with ...

Total, saturated fat linked to increased risk of lung cancer

July 28, 2017
(HealthDay)—High intake of total and saturated fat is associated with increased risk of lung cancer, according to research published online July 25 in the Journal of Clinical Oncology.

Autoantibodies may help detect lung cancer earlier

February 17, 2016
Preliminary research has identified autoantibodies, immune proteins found in the blood specific for one's own proteins, that can potentially detect lung cancer early by distinguishing between smokers with or without lung ...

Recommended for you

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

RUNX proteins act as regulators in DNA repair, study finds

August 15, 2018
A study by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has revealed that RUNX proteins are integral to efficient DNA repair via the Fanconi Anemia (FA) ...

Chemicals found in vegetables prevent colon cancer in mice

August 14, 2018
Chemicals produced by vegetables such as kale, cabbage and broccoli could help to maintain a healthy gut and prevent colon cancer, a new study from the Francis Crick Institute shows.

Researchers artificially generate immune cells integral to creating cancer vaccines

August 14, 2018
For the first time, Mount Sinai researchers have identified a way to make large numbers of immune cells that can help prevent cancer reoccurrence, according to a study published in August in Cell Reports.

Stress hormone is key factor in failure of immune system to prevent leukemia

August 14, 2018
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.

Medically underserved women in the Southeast rarely receive BRCA tests

August 14, 2018
Medically underserved women in the Southeast diagnosed with breast cancer or ovarian cancer missed out on genetic testing that could have helped them and their relatives make important decisions about their health, according ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.